A Study of AK131 in Patients With Advanced Solid Tumors

NCT ID: NCT06166888

Last Updated: 2024-01-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 130 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-10
• Study Completion Date: 2028-12-31

Brief Summary

This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AK131

Subjects will receive AK131 via intravenously (IV) Q2W or Q3W, up to 2 years

Group Type: EXPERIMENTAL

AK131

Intervention Type: DRUG

AK131 is an anti-PD-1 and CD73 bispecific antibody

Interventions

AK131

AK131 is an anti-PD-1 and CD73 bispecific antibody

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written and signed informed consent.

2. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.

3. Life expectancy ≥3 months.

4. Histologically or cytologically documented unresectable advanced or metastatic malignant tumor that has failed or intolerant of standard therapy, or for which no effective standard therapy is available.

5. Subject must have at least one measurable lesion according to RECIST Version1.1.

6. Adequate organ function.

7. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective barrier methods of contraception during the study and for 120 days after last dose of study drug.

Exclusion Criteria

1. Any malignancy other than the disease under study within the past 3 years except for radically cured local cancers.

2. Being involved in another clinical study, except for observational clinical studies or follow-up period of interventional studies.

3. Receipt of any anti-CD73 treatment.

4. Anticancer therapy within 4 weeks prior to the first dose of investigational product.

5. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.

6. Subjects with spinal cord compression or active brain metastases, except for subjects with untreated and asymptomatic brain metastases or with stable brain metastases after treatment.

7. Subjects with pleural effusion, pericardial effusion, or ascites requiring repeated drainage.

8. Subjects whose imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the study.

9. Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1.

10. Patients with clinically significant cardio-cerebrovascular disease.

11. Active autoimmune diseases or history of autoimmune diseases that may relapse.

12. History of interstitial lung disease or noninfectious pneumonitis.

13. Major surgery, trauma,unhealed wound, ulcer or fracture within 4 weeks prior to first dose of investigational product.

14. Any condition that required systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of investigational product.

15. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product.

16. Known allergy or reaction to any component of the AK131 formulation.

17. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.

18. Any other conditions that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Akeso

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jinming Yu

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Ting Liu, MD

Role: CONTACT

clinicaltrials@akesobio.com

+86(0760)8987 3999

Facility Contacts

Jinming Yu, PhD

Role: primary

sdyujinming@126.com

13806406293

Other Identifiers

AK131-101

Identifier Type: -

Identifier Source: org_study_id